Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Herpes Zoster Clinical Trial

Official title:

Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02075515
• Other study ID #: 117177
• Secondary ID: 2013-000373-76
• Status: Completed
• Phase: Phase 3
• Start date: August 13, 2014
• Est. completion date: April 25, 2016

Study information

• Verified date: April 2021
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 651
• Est. completion date: April 25, 2016
• Est. primary completion date: April 29, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

• A male or female aged 50 years or older at the time of the first vaccination.

• Written informed consent obtained from the subject.

• Female subjects of non-childbearing potential may be enrolled in the study.

• Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

• has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test on the day of vaccination, and

• has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of < 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.

• Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine (E.g. inactivated and subunit vaccines) within 8 days prior to or within 14 days after either dose of study vaccine.

• Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

• Previous vaccination against HZ or varicella.

• Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.

• History of HZ.

• Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.

• Acute disease and/or fever at the time of enrollment.

• Fever is defined as temperature = 37.5°C (99.5°F) on oral, axillary or tympanic route, or = 38.0°C (100.4°F) on rectal route. The preferred route for recording temperature in this study will be oral.

• Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.

• Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.

• Pregnant or lactating females.

• Females planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 4.

• Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.

• Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.

• Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.

Related Conditions & MeSH terms

• Herpes Zoster
• Herpes Zoster Vaccine

Intervention

Biological:
• Herpes Zoster vaccine (GSK 1437173A)
2 doses administered intramuscularly in deltoid region of non-dominant arm.

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Gent
Belgium	GSK Investigational Site	Wilrijk
Canada	GSK Investigational Site	Brampton	Ontario
Canada	GSK Investigational Site	Coquitlam	British Columbia
Canada	GSK Investigational Site	Sherbrooke	Quebec
United States	GSK Investigational Site	Mesa	Arizona
United States	GSK Investigational Site	Milford	Massachusetts
United States	GSK Investigational Site	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Belgium,  Canada, 

References & Publications (1)

Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine. 2017 Dec 4;35(48 Pt B):6700-6706. doi: 10.1016/j.vaccine.2017.10.017. Epub 2017 Oct 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value	Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was = 97 milli international units per milliliter (mIU/mL).	At Month 3
Secondary	Anti-gE Humoral Immunogenicity	Anti-gE antibody concentrations, were determined by ELISA, expressed as Geometric Mean Concentrations (GMCs), in milli international units per milliliter (mIU/mL).	At Month 0 and Month 3
Secondary	Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA	Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination = 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination = 4 fold the pre-vaccination antibody concentration.	At Month 3
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activities.	Within 7 days (Days 0-6) after each vaccine dose and across doses
Secondary	Number of Days With Any Solicited Local Symptoms	The number of days with any local symptoms reported during the solicited post-vaccination period.	During the 7 days (Days 0-6) after each vaccine dose
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature= temperature > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	Within 7 days (Days 0-6) after each vaccine dose and across doses
Secondary	Number of Days With Any Solicited General Symptoms	The number of days with any general symptoms reported during the solicited post-vaccination period.	During the 7 days (Days 0-6) after each vaccine dose
Secondary	Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology	From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 until study end (Month 14)
Secondary	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.	During 30 days (Days 0-29) after each vaccination
Secondary	Number of Subjects With Any Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 to study end (Month 14)

External Links

•   IPD for this study will be made available via the Clinical Study Data Request site.